Full Press Release Details
Alpha Tau to Host Conference Call to Discuss
Interim Results from First Three Patients Treated for Recurrent Glioblastoma
Jerusalem, May 8, 2026 - Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW)
("Alpha Tau", or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT
today announced that it will host a conference call and webcast on Monday, May 11, 2026 at 8:30am ET to discuss interim clinical data
from the first three patients treated in its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), also known as the
REGAIN (Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial.
Conference Call and Webcast Details
An archived webcast will be available following the event.
About the REGAIN Study
The clinical trial is expected to enroll up to ten U.S. patients with
recurrent glioblastoma not amenable for surgical resection who have undergone a prior course of central nervous system radiation. The
primary objective of the study is to evaluate the feasibility and safety of the treatment, following the Company's promising results
from pre-clinical studies. Additional information about the trial can be found at https://www.clinicaltrials.gov/study/NCT06910306
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company
that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology
was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed
to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When
the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with
the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor,
and to spare the healthy tissue around it.
Forward-Looking Statements
This press release includes "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including "anticipate,"
"will," "plan," "may," "continue," and similar expressions are intended to identify forward-looking
statements. In addition, any statements or information that refer to the Alpha DaRT treatment in GBM patients, including the expected
patient enrollment, benefits, safety, implementation, feasibility and go to market process, and other expectations, beliefs, plans, including
with respect to clinical trials, including the REGAIN study,, regulatory approvals and studies, are forward-looking. All forward-looking
statements are based upon Alpha Tau's current expectations and various assumptions. Alpha Tau believes there is a reasonable basis
for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not
prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of
various important factors, including, without limitation: (i) Alpha Tau's ability to receive regulatory approval for its Alpha DaRT
technology or any future products or product candidates; (ii) Alpha Tau's limited operating history; (iii) Alpha Tau's incurrence
of significant losses to date; (iv) Alpha Tau's need for additional funding and ability to raise capital when needed; (v) Alpha
Tau's limited experience in medical device discovery and development; (vi) Alpha Tau's dependence on the success and commercialization
of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau's clinical studies to predict final study results;
(viii) failure of Alpha Tau's early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau's
ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau's Alpha DaRT technology or any
future products or product candidates; (xi) Alpha Tau's exposure to patent infringement lawsuits; (xii) Alpha Tau's ability
to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq's listing standards; (xiv) costs related
to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption
"Risk Factors" in Alpha Tau's annual report filed on form 20-F with the SEC on March 9, 2026, and other filings that
Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results
to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements
represent management's estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking
statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause
its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau's views as of any date
subsequent to the date of this press release.
Investor Relations Contact: